CIK: 0001766721 · Show all filings
Period: Q4 2022 (← Previous) (Next →)
Filing Date: Feb 9, 2023
Total Value ($000): $151,470 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | 6,068,125 | $46,239 | 30.5% | $40.43 | -76.3% | COM | 10806X102 |
| — | Verona Pharma plc (VRNA) | 1,332,485 | $34,818 | 23.0% | $7.38 | — | SPONSORED ADS | 925050106 |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | 1,025,000 | $26,086 | 17.2% | $10.24 | +127.8% | COM | 87164F105 |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | 1,472,331 | $11,204 | 7.4% | $20.37 | -59.1% | COM | 61225M102 |
| ACRS | Aclaris Theraputics Inc. (ACRS) | 434,455 | $6,843 | 4.5% | $10.31 | +56.1% | COM | 00461U105 |
| BMEA | Biomea Fusion Inc. (BMEA) | 798,757 | $6,734 | 4.4% | $17.65 | -51.7% | COM | 09077A106 |
| — | Poseida Therapeutics Inc. (PSTX) | 1,043,267 | $5,529 | 3.7% | $8.87 | — | COM | 73730P108 |
| NUVB | Nuvation Bio Inc. (NUVB) | 2,541,009 | $4,879 | 3.2% | $11.18 | -81.9% | COM CL A | 67080N101 |
| — | Elevation Oncology Inc. (ELEV) | 2,834,910 | $2,693 | 1.8% | $13.57 | — | COM | 28623U101 |
| — | Reneo Pharmaceuticals Inc. (RPHM) | 886,075 | $2,065 | 1.4% | $9.33 | — | COM | 75974E103 |
| — | Spruce Biosciences, Inc. (SPRB) | 1,205,511 | $1,322 | 0.9% | $24.31 | — | COM | 85209E109 |
| — | Marker Therapeutics, Inc. (MRKR) | 3,142,857 | $849 | 0.6% | $4.35 | — | COM | 57055L107 |
| — | Aeglea Biotherapeutics Inc. (AGLE) | 1,691,151 | $761 | 0.5% | $8.00 | — | COM | 00773J103 |
| — | AVROBIO, Inc. (AVRO) | 1,009,779 | $717 | 0.5% | $16.72 | — | COM | 05455M100 |
| — | Viracta Therapeutics Inc. (VIRX) | 288,571 | $421 | 0.3% | $11.34 | — | COM | 92765F108 |
| — | Atreca Inc. (BCEL) | 387,653 | $311 | 0.2% | $18.84 | — | CL A COM | 04965G109 |